In the preceding three months, 4 analysts have released ratings for 4D Molecular Therapeutics (NASDAQ:FDMT), presenting a wide array of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $37.5, a high estimate of $39.00, and a low estimate of $36.00. A 2.6% drop is evident in the current average compared to the previous average price target of $38.50.

Deciphering Analyst Ratings: An In-Depth Analysis

A comprehensive examination of how financial experts perceive...